Research Square (Research Square),
Journal Year:
2023,
Volume and Issue:
unknown
Published: March 7, 2023
Abstract
The
purpose
of
this
study
was
to
explore
the
efficacy
radiomics
based
on
multisequence
MRI
predict
expression
PD-1/PD-L1
in
HCC.One
hundred
eight
patients
with
HCC
who
underwent
contrast-enhanced
2
weeks
before
surgical
resection
were
enrolled
retrospective
study.Corresponding
paraffin
sections
collected
for
immunohistochemistry
detect
PD-1
and
PD-L1.
All
randomly
divided
into
a
training
cohort
validation
at
ratio
7:3.The
features
extracted
from
axial
fat
suppression
T2-weighted
imaging
(FS-T2WI),
arterial
phase
(A)
portal
(P)
dynamic
MRI,
corresponding
feature
sets
generated.
least
absolute
shrinkage
selection
operator
(LASSO)
performed
select
optimal
analysis.
A
logistic
regression
analysis
construct
single-sequence
(FS-T2WI,
P)
(M)
models.
predictive
performance
judged
by
area
under
receiver
operating
characteristic
curve
(AUC)
cohorts.In
whole
cohort,
positive
43
PD-L1
34
patients.
AUC
values
FS-T2WI,
A,
P
M
models
0.696,
0.843,
0.863,
0.946
group
0.669,
0.792,
0.800
0.815
group,
respectively.The
0.731,
0.800,
0.831
0.621,
0.743,
0.771,and
0.810
respectively.
combined
model
(M
model)
better
than
other
results
suggest
that
had
potential
preoperative
HCC,
which
may
become
biomarker
ICI
treatment.
Scientific Reports,
Journal Year:
2023,
Volume and Issue:
13(1)
Published: May 12, 2023
Abstract
The
purpose
of
this
study
was
to
explore
the
effectiveness
radiomics
based
on
multisequence
MRI
in
predicting
expression
PD-1/PD-L1
hepatocellular
carcinoma
(HCC).
One
hundred
and
eight
patients
with
HCC
who
underwent
contrast-enhanced
2
weeks
before
surgical
resection
were
enrolled
retrospective
study.
Corresponding
paraffin
sections
collected
for
immunohistochemistry
detect
PD-1
PD-L1.
All
randomly
divided
into
a
training
cohort
validation
at
ratio
7:3.
Univariate
multivariate
analyses
used
select
potential
clinical
characteristics
related
PD-L1
expression.
Radiomics
features
extracted
from
axial
fat-suppression
T2-weighted
imaging
(FS-T2WI)
images
arterial
phase
portal
venous
dynamic
MRI,
corresponding
feature
sets
generated.
least
absolute
shrinkage
selection
operator
(LASSO)
optimal
analysis.
Logistic
regression
analysis
performed
construct
single-sequence
radiomic-clinical
models.
predictive
performance
judged
by
area
under
receiver
operating
characteristic
curve
(AUC)
cohorts.
In
whole
cohort,
positive
43
patients,
34
patients.
presence
satellite
nodules
served
as
an
independent
predictor
AUC
values
FS-T2WI,
phase,
models
0.696,
0.843,
0.863,
0.946
group
0.669,
0.792,
0.800
0.815
group,
respectively.
0.731,
0.800,
0.831
0.898
0.621,
0.743,
0.771,
0.810
0.779
combined
showed
better
performance.
results
suggest
that
model
has
predict
preoperative
HCC,
which
could
become
biomarker
immune
checkpoint
inhibitor
(ICI)-based
treatment.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(3), P. 1381 - 1381
Published: Jan. 23, 2024
Hepatocellular
carcinoma
(HCC)
remains
a
global
health
challenge
with
limited
treatment
options
and
poor
prognosis
for
advanced-stage
patients.
Recent
advancements
in
cancer
immunotherapy
have
generated
significant
interest
exploring
novel
approaches
to
combat
HCC.
One
such
approach
involves
the
unique
versatile
subset
of
T
cells
known
as
γδ
cells.
represent
distinct
lymphocytes
that
differ
from
conventional
αβ
terms
antigen
recognition
effector
functions.
They
play
crucial
role
immunosurveillance
against
various
malignancies,
including
studies
demonstrated
can
directly
recognize
target
HCC
cells,
making
them
an
attractive
candidate
immunotherapy.
In
this
article,
we
aimed
explore
exerted
by
context
We
investigate
strategies
designed
maximize
therapeutic
effectiveness
these
examine
challenges
opportunities
inherent
applying
research
findings
clinical
practice.
The
potential
bring
about
revolutionary
shift
capitalizing
on
attributes
offers
considerable
promise
enhancing
patient
outcomes,
warranting
further
investigation.
Journal of Clinical and Translational Hepatology,
Journal Year:
2024,
Volume and Issue:
000(000), P. 000 - 000
Published: Jan. 10, 2024
The
high
mortality
rate
in
hepatocellular
carcinoma
(HCC)
is
partially
due
to
the
fact
that
a
significant
number
of
patients
are
diagnosed
at
an
intermediate
or
advanced
stage,
with
surgical
treatment
options
unavailable.
Conversion
therapy,
which
involves
both
locoregional
and
systemic
treatments,
has
potential
downstage
tumors
selected
initially
unresectable
HCC,
thereby
making
possibility
potentially
increasing
long-term
survival.
To
optimize
conversion
rate,
it
necessary
maximize
successful
conversions
clearly
define
target
population
for
through
collaborative
effort.
In
this
review
article,
we
summarize
clinical
experience
evidence
therapy
'potentially
resectable'
HCC
from
four
perspectives:
1)
defining
2)
selecting
appropriate
strategy,
placing
emphasis
on
utilization
combination
exhibits
objective
response
3)
determining
timing
urgency
resection,
4)
promoting
adoption
multidisciplinary
team
model.
authors
optimistic
continuous
progress
deeper
understanding
success
will
increase,
overall
survival
be
prolonged.
Medicina,
Journal Year:
2023,
Volume and Issue:
59(8), P. 1427 - 1427
Published: Aug. 6, 2023
Background
and
Objectives:
Hepatocellular
carcinoma
(HCC)
is
the
leading
cause
of
liver
cancer
worldwide
has
a
high
mortality
rate.
Its
incidence
increased
due
to
metabolic-associated
disease
(MAFLD)
epidemics.
Liver
transplantation
surgery
remain
most
resolute
measures.
Despite
optimistic
use
multi-kinase
inhibitors,
namely
sorafenib,
co-existence
chronic
made
response
rate
low
in
these
patients.
Immune
checkpoint
inhibitors
(ICIs)
have
become
promising
hope
for
certain
advanced
solid
tumors
and,
also,
HCC.
Unfortunately,
large
cohort
patients
with
HCC
fail
respond
immunotherapy.
Materials
Methods:
We
conducted
narrative
search
on
main
medical
databases
original
articles,
reviews,
meta-analyses,
randomized
clinical
trials,
case
series
using
following
keywords
acronyms
their
associations:
hepatocellular
carcinoma,
immunotherapy,
gut
microbiota,
fecal
microbiota
transplantation.
Results:
ICIs
are
sufficiently
safe
treatment
option
In
detail,
they
significantly
improved
survival
prognosis
vs.
sorafenib.
Although
there
several
highlighted
mechanisms
resistance,
signature
can
be
used
both
as
biomarker
an
effect
enhancer.
Practically,
probiotic
dose-finding
weapons
that
increase
ICI’s
treatment-response-reducing
resistance
mechanisms.
Conclusion:
Immunotherapy
been
significant
step-up
treatment,
modulation
effective
liaison
its
efficacy.
BMC Cancer,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: April 16, 2025
This
study
evaluated
the
effectiveness
and
safety
of
tislelizumab
plus
lenvatinib
(TL
group)
monotherapy
(T
in
patients
with
stage
C
hepatocellular
carcinoma
(HCC)
according
to
Barcelona
Clinic
Liver
Cancer
(BCLC)
staging
system
after
failure,
it
analyzed
factors
influencing
TL
as
a
second-line
treatment.
retrospective
analysis
involved
51
treated
at
single
center
between
January
2019
July
2023.
Survival
outcomes
tumor
responses
were
compared
T
groups.
Prognostic
for
overall
survival
(OS)
progression-free
(PFS)
identified
using
Cox
proportional
hazard
regression
models.
Among
BCLC
advanced
HCC
who
experienced
treatment
median
PFS
was
significantly
longer
group
than
(6.8
months
vs.
4.5
months,
p
=
0.003),
OS
notably
extended
(14.0
10.4
0.012).
Although
disease
control
rate
(64%
53.8%,
0.461)
objective
response
(20%
7.7%,
0.202)
numerically
higher
group,
these
differences
did
not
reach
significance.
Child-Pugh
B
liver
function
independent
prognostic
poor
OS,
whereas
only
an
factor
PFS,
PFS.
Subgroup
demonstrated
benefit
A
12.0
0.013)
but
those
(7.7
6.1
0.225).
In
most
frequent
treatment-related
adverse
events
(AEs)
hand-foot
skin
reaction
(32%),
hypertension
(28%),
diarrhea
hypothyroidism
(20%).
Grade
3
or
AEs
occurred
24%
grade
AEs.
The
incidence
comparable
two
As
treatment,
combination
well
tolerated
associated
improved
versus
alone
HCC,
particularly
function.
Cancers,
Journal Year:
2023,
Volume and Issue:
15(13), P. 3434 - 3434
Published: June 30, 2023
Liver
cancer
is
a
complex
and
challenging
disease
with
limited
treatment
options
dismal
prognosis.
Understanding
the
underlying
molecular
mechanisms
driving
liver
progression
metastasis
crucial
for
developing
effective
therapeutic
strategies.
The
EPH/ephrin
system,
which
comprises
family
of
cell
surface
receptors
their
corresponding
ligands,
has
been
implicated
in
pathogenesis
HCC.
This
review
paper
aims
to
provide
an
overview
current
understanding
role
system
Specifically,
we
discuss
dysregulation
signaling
HCC
its
impact
on
various
cellular
processes,
including
proliferation,
migration,
invasion.
Overall,
emerges
as
compelling
multifaceted
player
biology.
Elucidating
precise
implications
responses
may
pave
way
novel
targeted
therapies
personalized
approaches
patients.
Further
research
warranted
unravel
full
potential
clinical
translation.
International Journal of Oncology,
Journal Year:
2023,
Volume and Issue:
64(1)
Published: Nov. 30, 2023
Charged
multivesicular
body
protein
3
(CHMP3)
is
an
elemental
constituent
of
the
endosomal
sorting
complex
required
for
transport
(ESCRT)
III,
whose
function
as
a
tumor
susceptibility
gene
in
development
liver
cancer
remains
unclear.
CHMP3
was
found
to
be
associated
with
pyroptosis
by
bioinformatics
analysis
data
from
patients
hepatocellular
carcinoma
(HCC)
The
Cancer
Genome
Atlas
database.
It
aimed
explore
role
and
potential
mechanisms
cancer.
expression
at
tissue
level
examined
using
immunohistochemistry
western
blot
analysis.
Subsequently,
HepG2
Huh‑7
cells
were
transfected
small
interfering
RNA
overexpression
plasmids
change
expression.
proliferative
capacity
colony
formation
Cell
Counting
Kit‑8
assays.
Wound
healing
Transwell
assays
used
examine
migratory
invasive
abilities
cells.
Transmission
electron
microscopy
observe
changes
cell
morphology.
Western
blotting
caspase‑1
signaling
pathway
related
proteins,
classic
pyroptosis.
In
addition,
xenograft
model
tumorigenic
ability
vivo.
results
demonstrated
that
upregulated
HCC
poor
prognosis.
Knockdown
or
inhibited
promoted
proliferation,
migration
invasion
showed
membrane
integrity
well
cytoplasmic
leakage.
Furthermore,
knockdown
may
activate
which
turn
inhibits
progression
cancer,
this
effect
can
reversed
inhibitor
AYC.
conclusion,
affect
through
caspase‑1‑mediated
pathway.
Human Gene Therapy,
Journal Year:
2024,
Volume and Issue:
35(5-6), P. 177 - 191
Published: Feb. 22, 2024
Oncolytic
viruses
(OVs)
are
appealing
anti-tumor
agents.
But
it
is
limited
in
its
effectiveness.
In
this
study,
we
used
combination
therapy
with
immune
checkpoint
inhibitor
to
enhance
the
antitumor
efficacy
of
OVs.
Using
reverse
genetics
technology,
rescued
an
oncolytic
influenza
virus
name
delNS1-GM-CSF
from
virus.
After
identifying
hemagglutination
and
50%
tissue
culture
infectivedose
(TCID
International Journal of General Medicine,
Journal Year:
2023,
Volume and Issue:
Volume 16, P. 467 - 480
Published: Feb. 1, 2023
Hepatocellular
carcinoma
(HCC)
is
one
of
the
most
common
malignant
tumors
that
lacks
an
efficient
therapeutic
approach
because
its
elusive
molecular
mechanisms.
This
study
aimed
to
investigate
biological
function
and
potential
mechanism
formin-binding
protein
4
(FNBP4)
in
HCC.FNBP4
expression
tissues
cells
were
detected
by
quantitative
real-time
PCR
(qRT‒PCR),
Western
blot,
immunohistochemistry
(IHC).
The
Kaplan-Meier
method
was
used
explore
correlation
between
FNBP4
clinical
survival.
MTT,
EdU
incorporation,
colony
formation,
Transwell
assays
performed
evaluate
cell
proliferation
migration
vitro.
Kyoto
Encyclopedia
Genes
Genomes
(KEGG)
pathway
analysis
FNBP4.
prognostic
risk
signature
nomogram
constructed
demonstrate
value
FNBP4.We
found
upregulated
patients
with
HCC
associated
poor
overall
survival
(OS).
Furthermore,
knockdown
inhibited
cells.
Then,
we
a
KEGG
coexpressed
genes
may
be
tumor-related
signaling
pathways
cuproptosis.
We
verified
could
cause
cycle
progression
inactivation
hippo
pathway.
A
containing
three
FNBP4-related
differentially
expressed
cuproptosis
regulators
(DECRs)
established
can
as
independent
factor
prognosis
HCC.
In
addition,
including
score
clinicopathological
factors
predict
patient
probabilities.FNBP4,
biomarker
cuproptosis,
promotes
metastasis.
provide
new
strategy
for
treatment
targeting
